Jerry Bagel

Mar 13, 2023 | jofskin.org | Lawrence Green |Jerry Bagel |George Han |Abby A. Jacobson |Martha Sikes

This work is licensed under a Creative Commons Attribution 4.0 International License. All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose.

Mar 13, 2023 | jofskin.org | Jerry Bagel |East Windsor |April Armstrong |Richard Warren

Main Article Content Keywords psoriasis, deucravacitinib, tyrosine kinase 2, phase 3 clinical trial, efficacy Abstract Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US FDA for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucravacitinib was significantly more efficacious than placebo or apremilast and was well tolerated in previous reports from the phase...